BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Phase 2

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Placebo
Drug: Daclatasvir
Drug: Pegylated interferon alfa-2a
Drug: Ribavirin

First Posted Date: 2010-12-09

Last Posted Date: 2015-12-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 196

Registration Number: NCT01257204

Locations: 🇺🇸
California Liver Institute, Los Angeles, California, United States
🇮🇹
Local Institution, Viale Del Policlinico, 155, Italy
🇺🇸
Options Health Research, Llc, Tulsa, Oklahoma, United States

and more 2 locations

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

Phase 1

Completed

Conditions: HCV (Genotype 1)

Interventions: Drug: INX-08189
Drug: Placebo matching with INX-08189
Drug: Ribavirin

First Posted Date: 2010-11-30

Last Posted Date: 2012-07-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT01250366

Safety Study of Abatacept to Treat Rheumatoid Arthritis

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-11-24

Last Posted Date: 2018-03-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8000

Registration Number: NCT01247766

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: BMS-908662
Drug: Ipilimumab

First Posted Date: 2010-11-22

Last Posted Date: 2013-06-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT01245556

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Jedd D. Wolchok, Md,Phd, New York, New York, United States

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Completed

Conditions: Chronic Myeloid Leukemia

First Posted Date: 2010-11-19

Last Posted Date: 2022-06-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1494

Registration Number: NCT01244750

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Peachtree Hematology-Oncology, Atlanta, Georgia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 139 locations

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: BMS-901608 (Elotuzumab) 20 mg
Biological: BMS-901608 (Elotuzumab) 10 mg

First Posted Date: 2010-11-16

Last Posted Date: 2018-02-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 7

Registration Number: NCT01241292

Locations: 🇯🇵
Local Institution, Niigata-shi, Niigata, Japan

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

Phase 1

Completed

Conditions: Diabetes

Interventions: Drug: BMS-903452
Drug: Placebo

First Posted Date: 2010-11-15

Last Posted Date: 2012-03-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 104

Registration Number: NCT01240980

Locations: 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
🇺🇸
Comprehensive Phase One, Miramar, Florida, United States

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Lymphoma
Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Drug: Dexamethasone (Oral)
Drug: Dexamethasone (IV)
Biological: Elotuzumab (BMS-901608; HuLuc63)

First Posted Date: 2010-11-11

Last Posted Date: 2022-06-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 646

Registration Number: NCT01239797

Locations: 🇺🇸
Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Ut Southwestern Medical Center, Dallas, Texas, United States

and more 36 locations

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Completed

Conditions: HIV

First Posted Date: 2010-11-07

Last Posted Date: 2013-09-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 525

Registration Number: NCT01236235

Locations: 🇪🇸
Local Institution, Zaragoza, Spain

Multiple Ascending Dose of BMS-911543

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: BMS-911543

First Posted Date: 2010-11-07

Last Posted Date: 2019-07-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 98

Registration Number: NCT01236352

Locations: 🇺🇸
The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States
🇦🇺
Local Institution, Melbourne, Victoria, Australia
🇺🇸
The Mount Sinai School Of Medicine, New York, New York, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy